Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
NASDAQ:REPL
Price:
7.65
USD
6.25%
Market Cap:
$631.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Replimune Group Inc
NASDAQ:REPL
|
US |
|
Tourmaline Bio Inc
NASDAQ:TRML
|
US |
|
F
|
First Midwest Bancorp Inc
F:FM6
|
US |
|
C
|
CanariaBio Inc
KOSDAQ:016790
|
KR |
|
W
|
World Fuel Services Corp
XBER:WFK
|
US |
|
A
|
Abercrombie & Fitch Co
F:AFT
|
US |
|
Tryg A/S
CSE:TRYG
|
DK |
|
Power Finance Corporation Ltd
NSE:PFC
|
IN |
|
C
|
Cancambria Energy Corp
XTSX:CCEC
|
CA |
|
O
|
Ossia International Ltd
SGX:O08
|
SG |
|
ASML Holding NV
AEX:ASML
|
NL |
|
C
|
Coupa Software Inc
F:2C0
|
US |
Multiples-Based Value
The
Multiples-Based Value for
Replimune Group Inc (REPL)
under the Base Case is
hidden
USD.
Compared with the current market price of 7.65 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
REPL Multiples-Based Value
LOCKED
Multiples Across Competitors
REPL Competitors Multiples
Replimune Group Inc Competitors
Replimune Group Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Replimune Group Inc
NASDAQ:REPL
|
609.2m USD | 0 | -1.9 | -1.3 | -1.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
384.5B USD | 6.2 | 90.8 | 15 | 20.8 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
362.4B USD | 111.6 | -1 741.9 | 16 180.3 | -1 827 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.6B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173B USD | 5.9 | 20.4 | 12.8 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD | 9.5 | 28.8 | 21.7 | 22.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
